{"id":"experimental-for-antifungals","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the specific molecular target is not publicly disclosed, antifungals in development typically work by disrupting ergosterol synthesis, inhibiting β-glucan synthase, or targeting other fungal-specific biosynthetic pathways. This Phase 3 candidate from AP-HP is being evaluated for efficacy and safety in treating systemic or invasive fungal infections.","oneSentence":"This experimental antifungal drug inhibits fungal cell wall or membrane synthesis to prevent fungal growth and proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:37.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive fungal infections (specific indication under Phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT06925321","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2025-08-26","conditions":"Invasive Mold Infections","enrollment":219},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT06666322","phase":"PHASE2, PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":"Hiv, Cryptococcal Meningitis","enrollment":2000},{"nctId":"NCT06789588","phase":"PHASE3","title":"Protocol for Improvement of Therapy With Warfarin","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pernambuco","startDate":"2024-10-21","conditions":"Atrial Fibrillation (AF)","enrollment":700},{"nctId":"NCT06892951","phase":"PHASE1, PHASE2","title":"CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2025-06","conditions":"Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections","enrollment":100},{"nctId":"NCT03059992","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2017-04-01","conditions":"Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis","enrollment":233},{"nctId":"NCT06376201","phase":"PHASE4","title":"A Clinical Study on the Efficacy and Safety of ABCD in the Treatment of Patients With Invasive Fungal Disease","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-04","conditions":"Invasive Fungal Disease","enrollment":125},{"nctId":"NCT05363449","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2022-02-17","conditions":"Tinea Cruris, Tinea Pedis","enrollment":42},{"nctId":"NCT03945448","phase":"PHASE2, PHASE3","title":"Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia","status":"RECRUITING","sponsor":"Makerere University","startDate":"2019-06-20","conditions":"Cryptococcal Meningitis","enrollment":356},{"nctId":"NCT05255016","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers","status":"UNKNOWN","sponsor":"Peschke GmbH","startDate":"2022-03-14","conditions":"Keratitis, Corneal Ulcer","enrollment":488},{"nctId":"NCT03897257","phase":"PHASE2","title":"A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2019-03-15","conditions":"Tinea Pedis","enrollment":240},{"nctId":"NCT03253094","phase":"PHASE2","title":"Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2017-08-01","conditions":"Candida Vulvovaginitis","enrollment":186},{"nctId":"NCT04680884","phase":"PHASE3","title":"Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-12-21","conditions":"Acute Respiratory Failure, Immunocompromised Patients","enrollment":420},{"nctId":"NCT04341402","phase":"PHASE2","title":"Systemic Uptake of Diclofenac Sodium in Combination With Miconazole as Antifungal Nail Gel When Applied Daily With Monitoring of Hepatic and Renal Enzymes, and Serum Levels of Diclofenac 12 Hours After Application, and at 3 and 6 Months Study","status":"UNKNOWN","sponsor":"William N Handelman","startDate":"2020-05-01","conditions":"Tinea Unguium, Onychomycosis","enrollment":30},{"nctId":"NCT04327011","phase":"PHASE1","title":"A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511","status":"TERMINATED","sponsor":"Tocagen Inc.","startDate":"2011-02","conditions":"Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":358,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental for antifungals","genericName":"Experimental for antifungals","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This experimental antifungal drug inhibits fungal cell wall or membrane synthesis to prevent fungal growth and proliferation. Used for Invasive fungal infections (specific indication under Phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}